On the other hand, the LCHFD maintains insulin levels and de novo lipogenesis Fasn gene expression similar to the control animals, protecting the liver against NAFLD development (Figure 5). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.